291 results on '"Henn, Matthew R."'
Search Results
2. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
3. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
4. Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus
5. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection
6. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
7. Isotopic Fractionation during Ammonium Assimilation by Basidiomycete Fungi and Its Implications for Natural Nitrogen Isotope Patterns
8. Reply to Lagier et al
9. The GAAS metagenomic tool and its estimations of viral and microbial average genome size in four major biomes.
10. Ecophysiology of δ 13 C and δ 15 N Isotopic Fractionation in Forest Fungi and the Roots of the Saprotrophic-Mycorrhizal Divide
11. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection
12. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
13. Assessment of a rationally-designed experimental microbial consortium to reduce systemic inflammation in a murine model of chemotherapy-induced mucositis.
14. 110: IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
15. Su1606: ENGRAFTMENT OF INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-109 IS DURABLE THROUGH 24 WEEKS IN A RANDOMIZED TRIAL (ECOSPOR III) FOR THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
16. Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants
17. Reemergence and Decline of Dengue Virus Serotype 3 in Puerto Rico
18. Rapid diversification of coevolving marine Synechococcus and a virus
19. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
20. Trends in Patterns of Dengue Transmission over 4 Years in a Pediatric Cohort Study in Nicaragua
21. Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
22. Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors.
23. 809 RAPID CONVERSION OF PRIMARY TO SECONDARY BILE ACIDS IN SUBJECTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) FOLLOWING SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC
24. Fr572 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
25. 681 SER-301, AN INVESTIGATIONAL, RATIONALLY-DESIGNED BACTERIAL CONSORTIUM FOR MILD-TO-MODERATE ULCERATIVE COLITIS, RECAPITULATES THE EFFECTS OF SER-287, A CONSORTIUM OF FIRMICUTE SPORES, ON REMISSION ASSOCIATED MICROBIAL METABOLITES AND HOST GENE EXPRESSION
26. Fr479 IN VIVO CHARACTERIZATION OF SER-301, AN INVESTIGATIONAL RATIONALLY-DESIGNED MICROBIOME THERAPEUTIC FOR PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS
27. Endurance, refuge, and reemergence of dengue virus type 2, Puerto Rico, 1986-2007
28. Mo1809 MICROBIOME AVATAR COLITIS MOUSE MODEL - A TRANSLATIONAL TOOL FOR IN VIVO CHARACTERIZATION OF HETEROGENEITY IN STOOL SAMPLES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
29. Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification
30. Ecophysiology of 13C and 15N isotopic fractionation in forest fungi and the roots of the saprotrophic-mycorrhizal divide
31. Growth-dependent stable carbon isotope fractionation by basidiomycete fungi: delta(sup)13C pattern and physiological process
32. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations
33. PriSM: a primer selection and matching tool for amplification and sequencing of viral genomes
34. 35 SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES IN VIVO AND IN VITRO METABOLOMIC CHANGES ASSOCIATED WITH CLINICAL REMISSION IN PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS
35. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
36. OR26-06 Fecal Microbiota Transplantation Trial for the Improvement of Metabolism (FMT-TRIM): A Randomized Double-Blind Placebo-Controlled Pilot Trial
37. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial
38. Enabling a Community to Dissect an Organism: Overview of the Neurospora Functional Genomics Project
39. Differential C isotope discrimination by fungi during decomposition of C(sub)3- and C(sub)4-derived sucrose
40. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
41. Genomic analysis of oceanic cyanobacterial myoviruses compared with T4-like myoviruses from diverse hosts and environments
42. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
43. Comparative analysis of genome fragments of Acidobacteria from deep Mediterranean plankton
44. A Set of Reference Sequences for the Hepatitis C Genotypes 4d, 4f, and 4k Covering the Full Open Reading Frame
45. Genomics of the fungal kingdom: Insights into eukaryotic biology
46. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
47. De novo assembly of highly diverse viral populations
48. 623 – Ser-287, an Investigational Microbiome Therapeutic, Induces Widespread Transcriptional Changes Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild-To-Moderate Ulcerative Colitis
49. 622 – Double-Blind Randomized Placebo-Controlled Trial of Weekly Fecal Microbiota Transplantation (FMT) Capsules in Obese Adults: Evaluating Microbiota Engraftment and Improvements in Insulin Sensitivity
50. Next-generation sequencing for HLA typing of class I loci
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.